Led by a team of former government intelligence and law enforcement specialists, ZENRS International offers a variety of security-focused services to clients worldwide. Whether conducting due diligence...
Global organizations need to build the capacity to effectively identify and monitor the most relevant geopolitical and financial trends that could affect their business. Failure to do so may expose them...
2024–25 is a critical period in modern global politics and economics. Geopolitical and financial trends are converging to reshape economies and societies, with significant implications for any company...
Third parties are typically a company’s main sources of exposure to legal, financial, reputational and strategic risks–and compliance officers are responsible for identifying and managing them...
Companies rely on global third parties and suppliers to deliver their products and services, but these third parties are increasingly becoming their main exposure to risk. In recent years, ten trends have...
Companies rely on third parties and suppliers around the world to deliver their products and services efficiently and effectively. But these third parties are also becoming a company’s main exposure...
Due Diligence
Patient safety, clinical trial management, mergers and acquisitions, research and development, sales and marketing, and pricing structures are all areas where failure to conduct due diligence and mitigate risk effectively can lead to reputational damage, financial loss, and regulatory enforcement action. In just a couple of decades, the pharmaceuticals and life sciences industry has changed beyond recognition in response to globalization and demand for new products. What does the current risk landscape look like for pharmaceuticals and life sciences sector?
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.